"We realize it's important to bring together, through partnership and collaboration, diverse scientific talent and capabilities to find the best possible outcomes for the people we serve."
ALAN PALKOWITZ, PH.D.
Vice President, Discovery Chemistry
Research and Technologies
EMERGING
BIOLOGY
Access to Lilly privileged compound libraries
DESIGN
Cheminformatics tools for designing molecules
SCREENING
Biological screening in strategic areas of interest
ANIMAL
HEALTH
Biological screening in strategic areas of interest
COMPOUND
ACQUISITION
Diversification of Lilly's compound collection
SYNTHESIS
Opportunity to access Automated Synthesis Lab
NEGLECTED
& TROPICAL
DISEASES
Work with on-profit public-private partnerships

For Scientists.
By Scientists.

MAKING LIVES BETTER. TOGETHER.

The Lilly Open Innovation Drug Discovery (OIDD) Program is founded on the belief that pharmaceutical companies, research institutions and academia share a mutual desire to advance innovative biomedical science. OIDD is a premier collaborative platform that unites global investigators with Lilly scientists to both uncover and create innovation that may positively impact the people we serve. Read more in the OIDD Brochure.